Midbrain atrophy patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome
- Authors
- Ahn, Jong Hyeon; Kim, Minkyeong; Kim, Ji Sun; Youn, Jinyoung; Jang, Wooyoung; Oh, Eungseok; Lee, Phil Hyu; Koh, Seong-Beom; Ahn, Tae-Beom; Cho, Jin Whan
- Issue Date
- 9월-2019
- Publisher
- ELSEVIER SCI LTD
- Keywords
- Progressive supranuclear palsy; Midbrain atrophy; Pons-to-midbrain ratio; Presymptomatic PSP; Biomarker; Richardson' s syndrome
- Citation
- PARKINSONISM & RELATED DISORDERS, v.66, pp.80 - 86
- Indexed
- SCIE
SCOPUS
- Journal Title
- PARKINSONISM & RELATED DISORDERS
- Volume
- 66
- Start Page
- 80
- End Page
- 86
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/63047
- DOI
- 10.1016/j.parkreldis.2019.07.009
- ISSN
- 1353-8020
- Abstract
- Introduction In the present study, midbrain atrophy and the pons-to-midbrain area ratio (P/M ratio) were investigated as diagnostic markers for presymptomatic progressive supranuclear palsy-Richardson's syndrome (Pre-PSP-RS). Methods: The present study included 27 patients with probable PSP-RS who underwent brain MRI at least twice before and after the development of clinical symptoms, age- and sex-matched participants with Parkinson's disease (PD, n = 27), and healthy controls (n = 27). The midbrain area, pons area, and P/M ratio of the Pre-PSP-RS, PD, and control subjects were measured using midsagittal images from brain MRI, and the parameters were compared among the groups. Results: The midbrain area decreased and the P/M ratio increased significantly in the Pre-PSP-RS patients compared with both the PD and control subjects (midbrain, Pre-PSP-RS vs. PD = 1.01 cm(2) vs. 1.29 cm(2), p < 0.001, Pre-PSP-RS vs. controls = 1.01 cm(2) vs. 1.29 cm(2), p < 0.001; P/M ratio, Pre-PSP-RS vs. PD = 5.27 vs. 4.03, p < 0.001, Pre-PSP-RS vs. controls = 5.27 cm(2) vs. 4.06 cm(2), p < 0.001). The P/M ratio had high sensitivity (vs. PD, 96.3%, vs. control, 88.9%) and specificity (vs. PD, 81.5%, vs. control, 96.3%) in differentiating Pre-PSP-RS patients from PD and control subjects. Conclusion: Midbrain atrophy precedes the clinical symptoms of PSP-RS and could be a useful diagnostic imaging biomarker for Pre-PSP-RS. Furthermore, this information could play an important role in the development of future treatment strategies.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.